Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RF2011
- Development stage
- Phase 1
- Lead developer
- Tianjin Pharmaceutical Holdings
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
RF2011 is an investigational antisense oligonucleotide (ASO) drug developed by Ruifu Pharmaceutical and Hongdi Biotechnology for the treatment of chronic hepatitis B. It is designed using a proprietary carbocyclic locked nucleic acid (cLNA) modification technology. RF2011 targets hepatitis B virus (HBV) transcripts to inhibit viral replication and reduce viral protein expression, including hepatitis B surface antigen (HBsAg). In preclinical studies, RF2011 demonstrated superior antiviral activity and longer-lasting efficacy compared to similar agents like bepirovirsen, along with rapid absorption following subcutaneous administration and a favorable safety profile.
- Other names
- RF2011 injectionRF-2011 injectionRF 2011 injectionRF2011 注射液
Beyond the preview
Go deeper on RF2011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RF2011.